Co-Chief Medical Officer, Director of Clinical Research at Frontier Dermatology
Gave a talk at Northeast Dermatology Conference on “A practical approach to using JAK inhibitors in dermatology”. Thanks for the great turnout! - via #Whova event app My 3-step approach to discussing the “boxed warning” : 1) NORMALIZE the boxed warning: we have a lot of medications in dermatology, including OTC, that also contain a boxed warning, but we continue to use these medications with regularity because we understand the context behind them. 2) CONTEXTUALIZE the boxed warning: different drugs, different diseases, different demographics WITHOUT a placebo group. This last point is crucial as we can interpret the ORAL surveillance study in 3 ways: A) Risk: JAKi > no treatment > TNFi B) Risk: JAKi = no treatment > TNFi C) Risk: no treatment > JAKi > TNFi *Time will tell but we also have to acknowledge that not treating/undertreating a disease has negative downstream effects as well. 3) REFERENCE long-term extension (which admittedly have limitations) and real world studies to show the incidence rates in patients who have AD but are not treated with a JAK inhibitor vs those who are treated with a JAK inhibitor. Spoiler alert: not much of an appreciable difference.
Such an awesome lecture! Thank you so much for your support!
Sheri Wallace
5mo
I needed this today. Had to go to urgent care and provider had no familiarity with this drug class. I am going to print this and drop off
The "Engine", James Song, always gives a great presentation!
Great to see you my friend!
Board Certified Dermatology Physician Associate and Diplomate Fellow, SDPA @yourdermsource
4moYour talks at Fall Clinical were exceptional and unparalleled. Thank you for sharing your expertise .